Welcome to our dedicated page for Aprea Therapeutics SEC filings (Ticker: APRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aprea Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage oncology company developing targeted therapies for biomarker-defined cancers. Its Form 8-K disclosures cover material events such as clinical updates for APR-1051, operating and financial results, corporate presentation updates, private-placement financing, capital-structure information, and Nasdaq listing-compliance notices.
Proxy materials for Aprea address annual meeting procedures and shareholder voting matters. The filing record also identifies the company’s common stock under the symbol APRE and provides formal disclosures tied to governance, financing activity, public-company reporting obligations, and the development status of its precision medicine oncology programs.
Aprea Therapeutics, Inc. director Michael Grissinger received equity compensation in the form of restricted stock units and stock options. On June 16, 2026, he was granted 3,135 restricted stock units that will vest and be settled in common stock on June 16, 2027, if he continues serving on the board through that date.
He also received stock options for 12,555 shares of common stock at an exercise price of $0.7293 per share, vesting in full on June 16, 2027 and expiring on June 16, 2036, subject to the same service-based condition. After these grants, he directly holds 6,024 shares of common stock and 12,555 stock options.
Aprea Therapeutics, Inc. director Gabriela Gruia received new equity compensation on June 16, 2026. She was granted 3,135 restricted stock units that will vest and settle in common stock on June 16, 2027, if she continues serving on the board through that date, with possible acceleration under certain conditions.
She also received stock options covering 12,555 shares of common stock at an exercise price of $0.7293 per share, which vest in full on June 16, 2027, subject to the same service condition and potential acceleration, and expire on June 16, 2036. Following these grants, she holds 4,180 shares of common stock directly.
Aprea Therapeutics director Richard Peters received equity-based compensation rather than trading shares on the market. On June 16, 2026, he was granted 3,135 restricted stock units that will vest and be settled in common stock on June 16, 2027, subject to his continued service on the board and potential acceleration conditions.
He also received stock options for 12,555 shares of common stock at an exercise price of $0.7293 per share, which vest in full on June 16, 2027 under the same service and acceleration conditions and expire on June 16, 2036. Following these awards, he holds 6,254 common shares directly.
Aprea Therapeutics director John B. Henneman III received new equity awards. He was granted 3,135 restricted stock units on June 16, 2026, which will vest and settle in common stock on June 16, 2027, if he remains on the board. He also received stock options for 12,555 shares of common stock at an exercise price of $0.7293 per share, vesting in full on June 16, 2027 and expiring on June 16, 2036. Following these awards, he directly holds 13,364 shares of common stock, while the options and restricted stock units represent additional potential future ownership.
Aprea Therapeutics director Jean-Pierre Bizzari received new equity awards. On June 16, 2026, he was granted 3,135 restricted stock units that will vest and settle in common stock on June 16, 2027, if he continues serving on the board and certain acceleration conditions do not apply.
He also received stock options covering 12,555 shares of common stock at an exercise price of $0.7293 per share, vesting in full on June 16, 2027 under the same service-based conditions. Following the grant, he directly holds 4,180 common shares, and the options expire on June 16, 2036.
Aprea Therapeutics director Marc Duey reported new equity awards rather than market trades. He received 3,135 restricted stock units on June 16, 2026, which are scheduled to vest and settle in common stock on June 16, 2027, subject to his continued service on the board and potential acceleration under certain conditions.
Duey was also granted stock options for 12,555 shares of common stock at an exercise price of $0.7293 per share, expiring on June 16, 2036. These options vest in full on June 16, 2027, subject to continued board service and similar acceleration terms. After these awards, he directly holds 259,290 common shares. An additional 602 shares are held indirectly by his spouse, and he disclaims beneficial ownership of those securities.
Aprea Therapeutics director Rifat Pamukcu reported new equity awards and updated holdings. On June 16, 2026, he received 3,135 restricted stock units that will vest and settle in common stock on June 16, 2027, subject to his continued board service and possible acceleration under certain conditions.
He was also granted stock options for 12,555 shares of common stock at an exercise price of $0.7293 per share, vesting in full on June 16, 2027 under similar service-based conditions. Following these awards, he directly holds 8,581 common shares and 12,555 options, and indirectly holds 14,108 common shares through ZNZ Holdings LLC, where he serves as Manager Partner.
Aprea Therapeutics director Bernd R. Seizinger reported equity awards that increase his stake in the company. He received 3,135 restricted stock units granted on June 16, 2026, which are scheduled to vest and settle in common stock on June 16, 2027, as long as he continues serving on the board. He was also granted stock options for 12,555 shares of common stock at an exercise price of $0.7293 per share, vesting in full on June 16, 2027 and expiring on June 16, 2036. After these grants, he directly holds 48,910 common shares.
Aprea Therapeutics, Inc. reported results of its 2026 annual stockholder meeting. Of 12,382,776 common shares entitled to vote, 8,268,451 shares, or approximately 66.8%, were represented, establishing a quorum.
Stockholders elected three Class I directors—Marc Duey, Richard Peters, M.D., and Bernd R. Seizinger, M.D., Ph.D.—to serve until the 2029 annual meeting or until successors are elected and qualified. EisnerAmper LLP was ratified as independent registered public accounting firm for fiscal year 2026.
Stockholders approved an amendment to the certificate of incorporation authorizing the board to implement a reverse stock split at a ratio between one-for-three and one-for-eight, with the exact ratio and timing left to the board’s discretion. They also approved, on a non-binding basis, executive compensation and, by advisory vote, indicated a preference for annual say-on-pay votes. An adjournment proposal related to the reverse split was also approved.
Aprea Therapeutics reports a Schedule 13G filing showing Vestal Point Capital and Ryan Wilder disclose beneficial ownership of 22,654,832 shares of Common Stock, representing 9.9% of the class.
The cover pages state the total includes 22,304,832 shares issuable upon exercise of warrants; certain warrants are subject to a 9.99% Blocker. The percentage is calculated using 11,452,452 shares outstanding as of March 16, 2026.